The global natural killer cells therapeutics market size was US$ 2,808.9 million in 2021. The global natural killer cells therapeutics market size is forecast to reach US$ 10,213.5 million by 2030, growing at a compound annual growth rate (CAGR) of 15.3% during the forecast period from 2022 to 2030.

Natural killer cells are granular lymphocytes with a wide surface area that respond fast to a pathogenic challenge. They are also in charge of creating immunoregulatory cytokines. Furthermore, they are an integral part of a human's innate immune system. NK cells are responsible for generating an immune response to cancer and viral diseases. These cells were employed in a variety of molecular and combinational therapy, resulting in a greater acceptance of these treatments. They can also utilize as an anti-cancer alternative to T cells and a therapeutic weapon against infectious disorders.

Factors Influencing Market Growth

Among the factors driving the global market include the rising adoption of NK cells for the treatment of cancer, infections, and liver diseases.
Growing awareness of immunotherapies among the population and rising R&D for the development of bi-specific antibodies for engaging NK cells in the destruction of tumor cells fuel the global market.
Higher expenses associated with the therapies and unfavorable side effects may slow down the overall market growth.
A substantial rise in R&D activities toward developing immunotherapy in the developing economies is forecast to offer lucrative opportunities for the global NK cell therapeutics market over the forecast period.
Impact Analysis of COVID-19

As a result of several precautionary lockdowns and other constraints imposed by governments worldwide, severe disruptions in manufacturing and supply-chain operations have occurred. Furthermore, consumer tastes have diminished as people were now much more focused on cutting non-essential expenses from their budgets as the outbreak has negatively impacted the overall economic condition of most people. Therefore, the COVID-19 pandemic had a negative impact on the global market.

Regional Insights

The Asia Pacific region is forecast to have lucrative growth in the market during the forecast period. As a result of the growing number of patients suffering from cancer, the rising geriatric population, and advancements in healthcare facilities. In addition, rising R&D activities toward the expansion of immunotherapies to treat various cancers and other disorders. Thus, these factors are driving the market growth in the region.

Leading Competitors

The leading prominent companies profiled in the global natural killer cells therapeutics market are:

Affimed N.V.
Fate Therapeutics
Fortress Biotech
Celgene Corporation
Glycostem Therapeutics BV
Nantkwest Incorporated
Nkarta Therapeutics, Incorporated
NKT Therapeutics Incorporated
Innate Pharma S.A.
Ziopharm Oncology Incorporated
Other Prominent Players
Scope of the Report

The global natural killer cells therapeutics market segmentation focuses on Therapeutics, Application, End-Users, and Region.

Segmentation based on Therapeutics

NK Cell Therapies
NK Cell Directed Antibodies
Segmentation based on Application

Gastrointestinal Diseases
Cancer
Immunoproliferative Disorders
Others
Segmentation based on End-Users

Research Centers & Institutes
Hospitals
Others
Segmentation based on Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America